Canertinib

DB05424InvestigationalSmall molecule

Canertinib is a pan-erbB tyrosine kinase inhibitor which work against esophageal squamous cell carcinoma in vitro and in vivo. Canertinib treatment significantly affects tumour metabolism, proliferation and hypoxia as determined...

Mechanism: CI-1033 effectively inhibits the growth of esophageal squamous cell carcinoma which co-expresses both EGFR and HER2 with the inhibition of phosphorylation of both MAPK and AKT. Some studies suggest that CI-1033 holds significant clinical potential in esophageal cancer.
Curator reviewed
Primary indication: Investigated for use/treatment in breast cancer and lung cancer.Curator reviewed
Formula / weight: C₂₄H₂₅ClFN₅O₃ · 485.938 g/mol (avg)
Code names: PD-183805

Resolves to

Compound

UNIIC78W1K5ASFCAS267243-28-7ChEMBLCHEMBL31965ChEBI61399PubChem156414

Structure

InChIKeyOMZCMEYTWSXEPZ-UHFFFAOYSA-NSMILESFC1=C(Cl)C=C(NC2=NC=NC3=CC(OCCCN4CCOCC4)=C(NC(=O)C=C)C=C23)C=C1

Targets

P00533EGFRQ15303ERBB4P04626ERBB2P31749AKT1

What you can answer from here — as of September 13, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

66Drug interactionsStructured to mechanism, not free text

1Clinical trialPhase, status and sponsor resolved per trial

24+ReferencesStructured and connected to the statements they support

Which drugs share a target with Canertinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account